GPER G-1 DEVELOPMENT GROUP
GPER G-1 Development Group develops a novel therapeutic for the treatment of diabetes and obesity. The company’s leading drug candidate for the treatment of obesity (through weight loss) and the treatment of diabetes and pre-diabetes (by restoring insulin sensitivity and glucose homeostasis) is Tespria, the GPER agonist G‑1.
GPER G-1 DEVELOPMENT GROUP
Industry:
Health Care Health Diagnostics Medical Therapeutics
Website Url:
http://www.gperg1.com
Status:
Active
Similar Organizations
3X Genetics
3X Genetics develops medical screening solutions to identify genetic disorders.
Endobetix
A Non-Surgical Solution to Treat Type 2 Diabetes and Obesity
Gismo Therapeutics
Gismo Therapeutics, a biotechnology startup, develops small-molecule therapeutics for the treatment of Alzheimer’s and Parkinson’s diseases.
I Heart Care
I Heart Care help keep track of health information both electronically and printed.
Innovative Healthcare
Innovative Healthcare develops therapeutics for the treatment of diabetes and chronic wounds.
POTS Treatment Center
The POTS Treatment Center offers patients collaborative, alternative care aimed at treating the whole person, not just the disorder.
Official Site Inspections
http://www.gperg1.com
- Host name: 130.0.153.160.host.secureserver.net
- IP address: 160.153.0.130
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
